论文部分内容阅读
目的:研究牙周治疗对牙周炎伴冠心病患者血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-ɑ(TNF-ɑ)及血脂水平的影响。方法:随机选取2013年-2015年在笔者所在医院进行治疗的牙周炎伴冠心病患者60例,按照随机原则分为两组,30例患者行常规内科维持治疗为对照组,此外30例患者在常规内科维持治疗的基础上进行牙周基础治疗为研究组,对比两组患者治疗后血清C反应蛋白、炎症因子及血脂水平的差异。结果:两组患者治疗前血清CRP、IL-6及TNF-ɑ等血清炎症因子和TC、TG、HDL-C、LDL-C及FG等血脂水平观察指标比较差异无统计学意义(P>0.05);治疗后,研究组患者血清CRP、IL-6及TNF-ɑ等血清炎症因子均较治疗前显著降低,并且低于对照组患者,组间比较差异有统计学意义(P<0.05);治疗后,对照组患者血清C反应蛋白、炎症因子及血脂水平与治疗前相比差异无统计学意义(P>0.05)。结论:对于牙周炎伴冠心病治疗可以显著降低其血清中CRP、IL-6及TNF-ɑ的含量,有助于后期冠心病的治疗,值得进行临床推广。
Objective: To study the effects of periodontal therapy on the levels of serum C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-ɑ) and serum lipids in patients with periodontitis and coronary heart disease. Methods: Sixty patients with periodontitis and coronary heart disease who were treated in the author’s hospital from 2013 to 2015 were randomly selected. They were divided into two groups according to the random principle. Thirty patients underwent routine medical maintenance therapy as the control group. In addition, 30 patients The basic periodontal treatment based on conventional medical maintenance treatment was taken as the study group. The difference of serum C-reactive protein, inflammatory factor and blood lipid levels was compared between the two groups after treatment. Results: There was no significant difference in serum lipid levels of CRP, IL-6 and TNF-血 between the two groups before treatment, TC, TG, HDL-C, LDL-C and FG After treatment, serum inflammatory factors such as serum CRP, IL-6 and TNF-ɑ in the study group were significantly lower than those before treatment, and were lower than those in the control group. There was significant difference between the two groups (P <0.05); After treatment, the levels of serum C-reactive protein, inflammatory cytokines and blood lipids in the control group were not significantly different from those before treatment (P> 0.05). Conclusion: The treatment of periodontitis with coronary heart disease can significantly reduce the content of CRP, IL-6 and TNF-γ in serum and contribute to the treatment of late stage coronary heart disease, which is worthy of clinical promotion.